PROTEINURIC KIDNEY DISEASE
Clinical trials for PROTEINURIC KIDNEY DISEASE explained in plain language.
Never miss a new study
Get alerted when new PROTEINURIC KIDNEY DISEASE trials appear
Sign up with your email to follow new studies for PROTEINURIC KIDNEY DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets genetic kidney disease in landmark trial
Disease control Recruiting nowThis study tests an experimental drug called VX-147 in adults and children with a genetic form of kidney disease linked to the APOL1 gene. The goal is to see if the drug can reduce protein in the urine and protect kidney function. About 466 participants will receive either VX-147…
Matched conditions: PROTEINURIC KIDNEY DISEASE
Phase: PHASE2, PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for cancer patients: Kidney-Sparing drug shows promise
Disease control Recruiting nowThis study tests a drug called sparsentan to reduce high levels of protein in the urine (proteinuria) caused by certain cancer treatments. About 20 adults with cancer who are taking VEGF inhibitors and have developed proteinuria will receive sparsentan for 8 weeks. The goal is to…
Matched conditions: PROTEINURIC KIDNEY DISEASE
Phase: PHASE1 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope for APOL1 kidney disease: targeted drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called MZE829 in 56 adults with chronic kidney disease caused by a specific genetic risk (APOL1). The goal is to see if the drug can safely reduce protein leakage into urine, a sign of kidney damage. Participants will take the drug for 12 wee…
Matched conditions: PROTEINURIC KIDNEY DISEASE
Phase: PHASE2 • Sponsor: Maze Therapeutics • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC